Merus
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Merus and other ETFs, options, and stocks.About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
MRUS Key Statistics
MRUS News
Merus (MRUS) stock has delivered an impressive run, up 39% over the past month and 124% year-to-date. Investors are taking note because these gains come amid co...
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Merus and keeping the price target at $97.00. Elevate Your Investing Strategy: Take advantag...
Oppenheimer says Merus’ (MRUS) colon cancer data update reinforces its “enthusiasm” for CytomX Therapeutics’ (CTMX) dose expansion data. The Merus Phase 2 resul...
Analyst ratings
88%
of 17 ratingsMore MRUS News
Needham analyst Ami Fadia has maintained their neutral stance on MRUS stock, giving a Hold rating yesterday. Elevate Your Investing Strategy: Take advantage of...
Merus (MRUS) N.V. announced initial interim clinical data as of an April 28, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemt...